Research ExplorerPublicationsOral supplementation with L-homoarginine in young volunteers

Oral supplementation with L-homoarginine in young volunteers

Standard

Oral supplementation with L-homoarginine in young volunteers. / Atzler, Dorothee; Schönhoff, Mirijam; Cordts, Kathrin; Ortland, Imke; Hoppe, Julia; Hummel, Friedhelm C; Gerloff, Christian; Jaehde, Ulrich; Jagodzinski, Annika; Böger, Rainer H; Choe, Chi-Un; Schwedhelm, Edzard.

In: BRIT J CLIN PHARMACO, Vol. 82, No. 6, 12.2016, p. 1477-1485.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Atzler, D, Schönhoff, M, Cordts, K, Ortland, I, Hoppe, J, Hummel, FC, Gerloff, C, Jaehde, U, Jagodzinski, A, Böger, RH, Choe, C-U & Schwedhelm, E 2016, 'Oral supplementation with L-homoarginine in young volunteers', BRIT J CLIN PHARMACO, vol. 82, no. 6, pp. 1477-1485. https://doi.org/10.1111/bcp.13068

APA

Atzler, D., Schönhoff, M., Cordts, K., Ortland, I., Hoppe, J., Hummel, F. C., Gerloff, C., Jaehde, U., Jagodzinski, A., Böger, R. H., Choe, C-U., & Schwedhelm, E. (2016). Oral supplementation with L-homoarginine in young volunteers. BRIT J CLIN PHARMACO, 82(6), 1477-1485. https://doi.org/10.1111/bcp.13068

Vancouver

Atzler D, Schönhoff M, Cordts K, Ortland I, Hoppe J, Hummel FC et al. Oral supplementation with L-homoarginine in young volunteers. BRIT J CLIN PHARMACO. 2016 Dec;82(6):1477-1485. https://doi.org/10.1111/bcp.13068

Bibtex

@article{b39b1317300c41899a14dad81798e524,
title = "Oral supplementation with L-homoarginine in young volunteers",
abstract = "AIMS: Low blood concentrations of the naturally occurring amino acid L-homoarginine (L-hArg) are related to impaired cardiovascular outcome and mortality in humans and animals. L-hArg is a weak substrate of nitric oxide synthase and an inhibitor of arginases in vitro. The aim of our study was to obtain kinetic and dynamic data after oral L-hArg supplementation.METHODS: In a double-blind, randomized, placebo-controlled crossover study, 20 young volunteers received 125 mg L-hArg once daily for 4 weeks. Kinetic parameters (Cmax , Tmax and AUC0-24h ) were calculated after ingestion of single and multiple doses of oral supplementation as primary endpoint. Secondary endpoints that were evaluated were routine laboratory, L-arginine, asymmetric dimethylarginine (ADMA), pulse wave velocity (PWV), augmentation index (AIx), flow-mediated vasodilatation (FMD), corticospinal excitability, i.e. motor threshold (MT), and cortical excitability, i.e. intracortical inhibition (ICI) and facilitation (ICF).RESULTS: One hour after ingestion (Tmax ), L-hArg increased the baseline L-hArg plasma concentration (2.87 ± 0.91 μmol l(-1) , mean ± SD) by 8.74 ± 4.46 [95% confidence intervals 6.65; 10.9] and 17.3 ± 4.97 [14.9; 19.6] μmol l(-1) (Cmax ), after single and multiple doses, respectively. Once-only and 4 weeks of supplementation resulted in AUCs0-24h of 63.5 ± 28.8 [50.0; 76.9] and 225 ± 78.5 [188; 2624] μmol l(-1) *h, for single and multiple doses, respectively. Routine laboratory parameters, L-arginine, ADMA, PWV, AIx, FMD, MT, ICI and ICF did not change by L-hArg supplementation compared to baseline.CONCLUSION: Once daily orally applied 125 mg L-hArg raises plasma L-hArg four- and sevenfold after single dose and 4 weeks of supplementation, respectively, and is safe and well tolerated in young volunteers.",
author = "Dorothee Atzler and Mirijam Sch{\"o}nhoff and Kathrin Cordts and Imke Ortland and Julia Hoppe and Hummel, {Friedhelm C} and Christian Gerloff and Ulrich Jaehde and Annika Jagodzinski and B{\"o}ger, {Rainer H} and Chi-Un Choe and Edzard Schwedhelm",
note = "{\textcopyright} 2016 The British Pharmacological Society.",
year = "2016",
month = dec,
doi = "10.1111/bcp.13068",
language = "English",
volume = "82",
pages = "1477--1485",
journal = "BRIT J CLIN PHARMACO",
issn = "0306-5251",
publisher = "Wiley-Blackwell",
number = "6",

}

RIS

TY - JOUR

T1 - Oral supplementation with L-homoarginine in young volunteers

AU - Atzler, Dorothee

AU - Schönhoff, Mirijam

AU - Cordts, Kathrin

AU - Ortland, Imke

AU - Hoppe, Julia

AU - Hummel, Friedhelm C

AU - Gerloff, Christian

AU - Jaehde, Ulrich

AU - Jagodzinski, Annika

AU - Böger, Rainer H

AU - Choe, Chi-Un

AU - Schwedhelm, Edzard

N1 - © 2016 The British Pharmacological Society.

PY - 2016/12

Y1 - 2016/12

N2 - AIMS: Low blood concentrations of the naturally occurring amino acid L-homoarginine (L-hArg) are related to impaired cardiovascular outcome and mortality in humans and animals. L-hArg is a weak substrate of nitric oxide synthase and an inhibitor of arginases in vitro. The aim of our study was to obtain kinetic and dynamic data after oral L-hArg supplementation.METHODS: In a double-blind, randomized, placebo-controlled crossover study, 20 young volunteers received 125 mg L-hArg once daily for 4 weeks. Kinetic parameters (Cmax , Tmax and AUC0-24h ) were calculated after ingestion of single and multiple doses of oral supplementation as primary endpoint. Secondary endpoints that were evaluated were routine laboratory, L-arginine, asymmetric dimethylarginine (ADMA), pulse wave velocity (PWV), augmentation index (AIx), flow-mediated vasodilatation (FMD), corticospinal excitability, i.e. motor threshold (MT), and cortical excitability, i.e. intracortical inhibition (ICI) and facilitation (ICF).RESULTS: One hour after ingestion (Tmax ), L-hArg increased the baseline L-hArg plasma concentration (2.87 ± 0.91 μmol l(-1) , mean ± SD) by 8.74 ± 4.46 [95% confidence intervals 6.65; 10.9] and 17.3 ± 4.97 [14.9; 19.6] μmol l(-1) (Cmax ), after single and multiple doses, respectively. Once-only and 4 weeks of supplementation resulted in AUCs0-24h of 63.5 ± 28.8 [50.0; 76.9] and 225 ± 78.5 [188; 2624] μmol l(-1) *h, for single and multiple doses, respectively. Routine laboratory parameters, L-arginine, ADMA, PWV, AIx, FMD, MT, ICI and ICF did not change by L-hArg supplementation compared to baseline.CONCLUSION: Once daily orally applied 125 mg L-hArg raises plasma L-hArg four- and sevenfold after single dose and 4 weeks of supplementation, respectively, and is safe and well tolerated in young volunteers.

AB - AIMS: Low blood concentrations of the naturally occurring amino acid L-homoarginine (L-hArg) are related to impaired cardiovascular outcome and mortality in humans and animals. L-hArg is a weak substrate of nitric oxide synthase and an inhibitor of arginases in vitro. The aim of our study was to obtain kinetic and dynamic data after oral L-hArg supplementation.METHODS: In a double-blind, randomized, placebo-controlled crossover study, 20 young volunteers received 125 mg L-hArg once daily for 4 weeks. Kinetic parameters (Cmax , Tmax and AUC0-24h ) were calculated after ingestion of single and multiple doses of oral supplementation as primary endpoint. Secondary endpoints that were evaluated were routine laboratory, L-arginine, asymmetric dimethylarginine (ADMA), pulse wave velocity (PWV), augmentation index (AIx), flow-mediated vasodilatation (FMD), corticospinal excitability, i.e. motor threshold (MT), and cortical excitability, i.e. intracortical inhibition (ICI) and facilitation (ICF).RESULTS: One hour after ingestion (Tmax ), L-hArg increased the baseline L-hArg plasma concentration (2.87 ± 0.91 μmol l(-1) , mean ± SD) by 8.74 ± 4.46 [95% confidence intervals 6.65; 10.9] and 17.3 ± 4.97 [14.9; 19.6] μmol l(-1) (Cmax ), after single and multiple doses, respectively. Once-only and 4 weeks of supplementation resulted in AUCs0-24h of 63.5 ± 28.8 [50.0; 76.9] and 225 ± 78.5 [188; 2624] μmol l(-1) *h, for single and multiple doses, respectively. Routine laboratory parameters, L-arginine, ADMA, PWV, AIx, FMD, MT, ICI and ICF did not change by L-hArg supplementation compared to baseline.CONCLUSION: Once daily orally applied 125 mg L-hArg raises plasma L-hArg four- and sevenfold after single dose and 4 weeks of supplementation, respectively, and is safe and well tolerated in young volunteers.

U2 - 10.1111/bcp.13068

DO - 10.1111/bcp.13068

M3 - SCORING: Journal article

C2 - 27434056

VL - 82

SP - 1477

EP - 1485

JO - BRIT J CLIN PHARMACO

JF - BRIT J CLIN PHARMACO

SN - 0306-5251

IS - 6

ER -